Top 10 Companies in the 1,3,6‑Trimethyl uracil (CAS 13509‑52‑9) Market (2026): Market Leaders Powering Global Pharmaceutical Innovation

MARKET INSIGHTS

Global 1,3,6‑Trimethyl uracil (CAS 13509‑52‑9) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.7 million by 2034, reflecting a steady expansion during the forecast period.

1,3,6‑Trimethyl uracil is a methylated derivative of uracil, a naturally occurring pyrimidine nucleobase. Identified by CAS number 13509‑52‑9, this specialty fine chemical serves as a key intermediate in the synthesis of pharmaceutical compounds, including theophylline‑related xanthine derivatives and other biologically active molecules. Its precise structural features make it a valuable building block in medicinal chemistry and nucleoside analog development.

The market continues to expand due to rising demand from the pharmaceutical and biotechnology sectors, where the compound functions as a critical synthetic intermediate. Enhanced research activities in nucleoside chemistry and a growing focus on novel therapeutic agents further sustain demand. The compound’s role in producing bronchodilatory and stimulant properties keeps it relevant across global drug discovery pipelines.

1,3,6‑Trimethyl uracil (CAS 13509‑52‑9) Market – View in Detailed Research Report

TOP 10 COMPANIES

1️⃣ Finetech Industry Limited

Headquarters: Shenzhen, China
Key Offering: Pharmaceutical‑grade 1,3,6‑Trimethyl uracil

Finetech has built a reputation for delivering high‑purity intermediates to API manufacturers. Their process emphasizes strict control of regio‑selectivity, reducing isomeric by‑products and ensuring consistent supply for complex synthesis routes.

Growth Initiatives: Investment in automated synthesis platforms to scale production and reduce batch variability.

• Enhanced process automation
• Expanded API customer base
• Strategic partnerships with CROs

2️⃣ Career Henan Chemical Co., Ltd.

Headquarters: Zhengzhou, China
Key Offering: Research‑grade 1,3,6‑Trimethyl uracil

Career Henan specializes in catalog and custom synthesis, offering rapid turnaround for academic and industrial researchers. Their focus on analytical validation supports stringent regulatory requirements.

Growth Initiatives: Development of a digital ordering platform to streamline customer interactions.

• Online order portal
• Real‑time inventory tracking
• Integrated SDS and CoA delivery

3️⃣ Zibo Hangyu Biotechnology Development Co., Ltd.

Headquarters: Zibo, China
Key Offering: Custom synthesis services

Zibo Hangyu offers tailored synthesis for niche intermediates, positioning itself as a go‑to supplier for complex nucleoside analog projects.

Growth Initiatives: Expansion of GMP‑qualified facilities to meet global API demand.

• GMP certification
• Process scalability
• Quality assurance integration

4️⃣ Hangzhou Dayangchem Co. Ltd.

Headquarters: Hangzhou, China
Key Offering: Pharmaceutical‑grade 1,3,6‑Trimethyl uracil

Dayangchem focuses on high‑purity intermediates for antiviral drug development, leveraging a robust supply chain to support fast‑track projects.

Growth Initiatives: Collaboration with academic institutions to co‑develop new synthesis routes.

• Academic partnerships
• Process innovation
• Rapid prototyping

5️⃣ Tokyo Chemical Industry (TCI)

Headquarters: Tokyo, Japan
Key Offering: Premium 1,3,6‑Trimethyl uracil with ISO certifications

TCI’s commitment to quality and regulatory compliance makes it a preferred supplier for Western markets, offering fast delivery and comprehensive documentation.

Growth Initiatives: Development of green chemistry processes to reduce solvent usage.

• Solvent‑recycling systems
• Eco‑friendly synthesis
• Reduced carbon footprint

6️⃣ Ningbo Inno Pharmchem Co., Ltd.

Headquarters: Ningbo, China
Key Offering: Custom synthesis and API support

Inno Pharmchem provides end‑to‑end solutions for drug discovery teams, combining synthesis expertise with analytical support.

Growth Initiatives: Integration of AI‑driven reaction optimization.

• AI reaction planning
• Process data analytics
• Improved yield prediction

7️⃣ Biosynth Carbosynth

Headquarters: Basel, Switzerland
Key Offering: High‑purity 1,3,6‑Trimethyl uracil

Biosynth Carbosynth serves the European market with stringent quality controls and rapid turnaround for research laboratories.

Growth Initiatives: Expansion of on‑demand synthesis capabilities.

• Rapid synthesis
• Custom purity levels
• Customer‑specific CoA

8️⃣ LEAP Chem Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Research‑grade intermediates

LEAP Chem focuses on delivering reliable supply for medicinal chemistry programs, maintaining a strong presence in the Asia‑Pacific region.

Growth Initiatives: Strengthening supply chain resilience through diversified raw material sourcing.

• Supplier diversification
• Inventory buffers
• Risk mitigation

9️⃣ MedChemExpress LLC

Headquarters: New Jersey, USA
Key Offering: Research‑grade 1,3,6‑Trimethyl uracil

MedChemExpress provides a comprehensive catalog of fine chemicals, supporting academic and industrial research with detailed analytical data.

Growth Initiatives: Launch of a subscription service for recurring orders.

• Subscription model
• Automated billing
• Priority delivery

🔟 Chongqing Chemdad Co., Ltd.

Headquarters: Chongqing, China
Key Offering: Custom synthesis and analytical support

Chemdad specializes in complex heterocyclic intermediates, catering to CROs and API developers with a focus on process efficiency.

Growth Initiatives: Investment in rapid synthesis technologies.

• Fast‑track synthesis
• Real‑time monitoring
• Reduced lead times

Download FREE Sample Report

Get Full Report

OUTLOOK

Over the next decade, the 1,3,6‑Trimethyl uracil market is expected to maintain a robust trajectory, driven by continued investment in antiviral and oncology drug discovery. The compound’s role as a versatile intermediate will keep it integral to emerging therapeutic platforms, particularly as precision medicine and biologics gain prominence.

FUTURE TRENDS

• Integration of 1,3,6‑Trimethyl uracil into mRNA and gene‑editing libraries, expanding its utility beyond traditional small‑molecule synthesis.
• Adoption of digital supply‑chain tools for real‑time tracking of purity and compliance data, enhancing transparency for regulated markets.
• Shift toward green chemistry approaches, reducing solvent footprints and aligning with sustainability mandates.
• Expansion of custom synthesis services to accommodate rapid‑cycle drug discovery programs, offering gram‑to‑kilogram scale production.